Compare Deere & Company (DE) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deere & Company vs Hims and Hers Health Inc — how do they compare? Deere & Company trades at $582.07 (market cap $157.75B), while Hims and Hers Health Inc trades at $35.3 (market cap $8.14B). The key difference: Deere & Company is far larger — about 19.4× Hims and Hers Health Inc's market cap, and Deere & Company pays a 1.11% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| DE | HIMS | |
|---|---|---|
Market Cap | $157.75B | $8.14B |
Sector | Industrials | Health |
52-Week High | $662.49 | $66.18 |
52-Week Low | $439.11 | $14.52 |
Enterprise Value | $212.58B | $8.52B |
Dividend Yield | 1.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $585.64, down 0.21% on the day, with a bearish technical signal from moving averages and oscillators. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Revenue declined to $44.67B in 2025, though net income margin remains solid at 10.33%. Recent news highlights a $20B precision agriculture initiative and regulatory agreements enhancing farmer access to repair tools.
The outlook is mixed: analyst consensus targets $676.08 (15% upside) with 41% buy ratings, but technicals and declining revenue pose near-term risks. Key opportunities include margin strength and agtech growth; risks involve cyclical farming demand and high debt levels. Investors should weigh fundamental resilience against sector headwinds.
Hims & Hers Health trades at $34.38, showing no change in the last session. The stock exhibits a bullish technical setup with moving averages supporting upward momentum, while oscillators remain neutral. Recent earnings have been mixed, with Q1 2026 missing expectations, but revenue growth remains positive. Analyst sentiment is divided with a 35% buy rating, and the consensus price target is $33.57. News highlights include expansion in weight-loss treatments and a new JPMorgan receivables facility.
The outlook for HIMS is cautiously optimistic, driven by growth in telehealth and weight-loss segments, but high valuation multiples and recent net income declines pose risks. Investment opportunity lies in market expansion and subscriber growth, while execution risks and competitive pressures require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
